India, March 17 -- AstraZeneca Pharma India Ltd. (AZPIL) has announced that the Central Drugs Standard Control Organisation (CDSCO) has granted approval for an additional indication of Durvalumab.

The therapy can now be used to treat patients with unresectable hepatocellular carcinoma (uHCC) who have not previously received systemic treatment.

Hepatocellular carcinoma (HCC) remains a major global health challenge, ranking as the sixth most common cancer and the third leading cause of cancer-related deaths worldwide.

The approval is supported by findings from the Phase III HIMALAYA trial, which evaluated durvalumab both as a monotherapy and in combination with tremelimumab under the STRIDE regimen.

According to Praveen Rao Akkinepally,...